Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

  • Showing results for a modified search because your search retrieved no results.
1.

Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.

Tendulkar RD, Hunter GK, Reddy CA, Stephans KL, Ciezki JP, Abdel-Wahab M, Stephenson AJ, Klein EA, Mahadevan A, Kupelian PA.

Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):94-9. doi: 10.1016/j.ijrobp.2013.05.044.

PMID:
23920389
2.

Intraoperative radiation therapy with the photon radiosurgery system in locally advanced and recurrent rectal cancer: retrospective review of the Cleveland clinic experience.

Guo S, Reddy CA, Kolar M, Woody N, Mahadevan A, Deibel FC, Dietz DW, Remzi FH, Suh JH.

Radiat Oncol. 2012 Jul 20;7:110. doi: 10.1186/1748-717X-7-110.

3.

Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy.

Tendulkar RD, Reddy CA, Stephans KL, Ciezki JP, Klein EA, Mahadevan A, Kupelian PA.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1397-404. doi: 10.1016/j.ijrobp.2011.04.042. Epub 2011 Jun 12.

PMID:
21665379
4.

Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function.

Pahlajani G, Raina R, Jones JS, Burdick M, Ali M, Li J, Mahadevan A, Ciezki J, Zippe C.

BJU Int. 2010 Nov;106(10):1524-7. doi: 10.1111/j.1464-410X.2010.09343.x.

5.

Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy?

Klein EA, Ciezki J, Kupelian PA, Mahadevan A.

Urol Oncol. 2009 Jan-Feb;27(1):67-71. doi: 10.1016/j.urolonc.2008.04.001. Review.

PMID:
19111801
6.

Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer.

Burdick MJ, Reddy CA, Ulchaker J, Angermeier K, Altman A, Chehade N, Mahadevan A, Kupelian PA, Klein EA, Ciezki JP.

Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1439-45. doi: 10.1016/j.ijrobp.2008.07.033. Epub 2008 Oct 28.

PMID:
18963536
7.

Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.

Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A.

Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1424-30. Epub 2007 Jun 4.

PMID:
17544601
8.

Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for localized adenocarcinoma of prostate.

Quan AL, Ciezki JP, Reddy CA, Angermeier K, Ulchaker J, Mahadevan A, Chehade N, Altman A, De Oreo G, Klein EA.

Urology. 2006 Dec;68(6):1237-41.

PMID:
17169646
9.

Aggressiveness of familial prostate cancer.

Kupelian PA, Reddy CA, Reuther AM, Mahadevan A, Ciezki JP, Klein EA.

J Clin Oncol. 2006 Jul 20;24(21):3445-50.

PMID:
16849760
10.

PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.

Ciezki JP, Reddy CA, Garcia J, Angermeier K, Ulchaker J, Mahadevan A, Chehade N, Altman A, Klein EA.

Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):512-7. Epub 2005 Oct 6.

PMID:
16213667
11.

A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy.

Ciezki JP, Klein EA, Angermeier K, Ulchaker J, Chehade N, Altman A, Mahadevan A, Reddy CA.

Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1347-50.

PMID:
15590163

Supplemental Content

Loading ...
Support Center